Abstract
Background Population-level viral load distribution, measured by cycle threshold (Ct), has been demonstrated to enable real-time estimation of Rt for SARS-CoV-2 ancestral strain. Generalisability of the framework under different circulating variants and pre-existing immunity remains unclear.
Aim This study aimed to examine the impact of evolving variants and population immunity on the generalizability of Ct-based transmission estimation framework.
Methods We obtained the first Ct record of local COVID-19 cases from July 2020 to January 2023 in Hong Kong. We modeled the association between daily viral load distribution and the conventional estimates of Rt based on case count. We trained the model using data from wave 3 (i.e., ancestral strain with minimal population immunity) and predicted Rt for wave 5, 6 and 7 (i.e., omicron subvariants with > 70% vaccine coverage). Cross-validation was performed by training on the other 4 waves. Stratification analysis by disease severity was conducted to evaluate the impact of the changing severity profiles.
Results Trained with the ancestral dominated wave 3, our model provided accurate estimation of Rt, with the area under the ROC curve of 0.98 (95% confidence interval: 0.96, 1.00), 0.62 (95% CI: 0.53, 0.70) and 0.80 (95% CI: 0.73, 0.88) for three omicron dominated waves 5 to 7, respectively. Models trained on the other four waves also had high accuracy. Stratification analysis suggested potential impact of case severity on model estimation, which coincided with the fluctuation of sampling delay.
Discussion Our findings suggested that incorporating population viral shedding can provide accurate real-time estimation of transmission with evolving variants and population immunity. Application of the model needs to account for sampling delay.
Competing Interest Statement
B.J.C. consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Roche, Sanofi Pasteur, and Pfizer. The remaining authors declare no competing interests.
Funding Statement
This study was funded by the Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong Special Administrative Region (grant no. 22210552, B.Y.), the Theme-based Research Scheme (Project No. T11-705/21-N; B.J.C.) and the general research fund (Project No. 17100822; T.K.T.) of the Research Grants Council of the Hong Kong SAR Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was obtained from the Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
